The autophagy machinery has been shown to mediate host responses against a variety of infectious agents. These responses include the lysosomal degradation of specific pathogens via canonical autophagy, as well interferon-y-dependent killing of other pathogens via non-degradative pathways. Developing small molecules that enhance autophagy (ATG) protein-dependent pathways may have the potential to yield therapeutics against a broad spectrum of organisms. The proposed project applies next-generation synthetic chemistry and high-throughput screening to discover novel enhancers of ATG-mediated defense to pathogen infection. The project includes both phenotypic and target-based screens to discover modulators of autophagy and ATG-dependent processes, which will be tested for their activity against a range of pathogens of interest to the NIAID. Compounds with broad activity will be characterized for their mechanisms-of-action and developed further through medicinal chemistry to yield therapeutic leads suitable for testing treatment strategies in animal studies.

Public Health Relevance

The development of therapeutics that prevent or treat infection by a broad range of pathogens is an urgent and unmet need for drug discovery. A drug that enhances the inherent ability of infected cells to clear pathogens within them may form the basis of a broad spectrum therapy, and represents a promising but untested strategy. The leads discovered in this project will enable the academic and pharmaceutical research communities to test, in animals, whether specific defense pathways (canonical and non-canonical autophagy) can be exploited for therapeutic benefit. .

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
1U19AI109725-01
Application #
8655106
Study Section
Special Emphasis Panel (ZAI1-LR-M (J1))
Project Start
Project End
Budget Start
2014-03-01
Budget End
2015-02-28
Support Year
1
Fiscal Year
2014
Total Cost
$2,026,830
Indirect Cost
$171,978
Name
Washington University
Department
Type
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Doench, John G; Fusi, Nicolo; Sullender, Meagan et al. (2016) Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat Biotechnol 34:184-91
DeJesus, Rowena; Moretti, Francesca; McAllister, Gregory et al. (2016) Functional CRISPR screening identifies the ufmylation pathway as a regulator of SQSTM1/p62. Elife 5:
Lu, Qun; Yokoyama, Christine C; Williams, Jesse W et al. (2016) Homeostatic Control of Innate Lung Inflammation by Vici Syndrome Gene Epg5 and Additional Autophagy Genes Promotes Influenza Pathogenesis. Cell Host Microbe 19:102-13
Lassen, Kara G; McKenzie, Craig I; Mari, Muriel et al. (2016) Genetic Coding Variant in GPR65 Alters Lysosomal pH and Links Lysosomal Dysfunction with Colitis Risk. Immunity 44:1392-405
Orchard, Robert C; Wilen, Craig B; Doench, John G et al. (2016) Discovery of a proteinaceous cellular receptor for a norovirus. Science 353:933-6
Wang, Chenran; Chen, Song; Yeo, Syn et al. (2016) Elevated p62/SQSTM1 determines the fate of autophagy-deficient neural stem cells by increasing superoxide. J Cell Biol 212:545-60
Dong, Xiaonan; Cheng, Adam; Zou, Zhongju et al. (2016) Endolysosomal trafficking of viral G protein-coupled receptor functions in innate immunity and control of viral oncogenesis. Proc Natl Acad Sci U S A 113:2994-9
Heath, Robert J; Goel, Gautam; Baxt, Leigh A et al. (2016) RNF166 Determines Recruitment of Adaptor Proteins during Antibacterial Autophagy. Cell Rep 17:2183-2194
O'Connell, Daniel J; Kolde, Raivo; Sooknah, Matthew et al. (2016) Simultaneous Pathway Activity Inference and Gene Expression Analysis Using RNA Sequencing. Cell Syst 2:323-34
Pfeiffer, Julie K; Virgin, Herbert W (2016) Viral immunity. Transkingdom control of viral infection and immunity in the mammalian intestine. Science 351:

Showing the most recent 10 out of 50 publications